8-K: DIH Holding US, Inc. Provides Updated Financials Following Business Combination

DIH Holding US, Inc. releases updated financial information, including unaudited results through December 31, 2023, following its business combination with Aurora Technology Acquisition Corp.

Summary

• DIH Holding US, Inc. has released updated financial information following its merger with Aurora Technology Acquisition Corp. (ATAK).
• The company's fiscal year end has changed from December 31 to March 31.
• The provided financials include unaudited results for the nine months ended December 31, 2023, for DIH Holding US, Inc. (Nevada).
• Pro forma financial data through December 31, 2023, is also included, reflecting the impact of the business combination.
• DIH's revenue for the nine months ended December 31, 2023, was $47.1 million, compared to $33.2 million for the same period in 2022.
• The company's net loss for the nine months ended December 31, 2023, was $4.2 million, compared to a $6.7 million loss for the same period in 2022.
• The company had cash and cash equivalents of $2.8 million as of December 31, 2023.
• The company's accumulated deficit was $(33.9) million as of December 31, 2023.
• The company is evaluating its ability to continue as a going concern due to the recent business combination.

Sentiment

Score: 5

Explanation: The document presents mixed signals. While there is strong revenue growth and a reduction in net losses, the company's accumulated deficit, going concern evaluation, and reliance on debt financing raise concerns. The sentiment is neutral to slightly negative.

Positives

• Revenue increased significantly by 42.1% year-over-year for the nine months ended December 31, 2023.
• Net losses decreased from $6.7 million to $4.2 million for the nine months ended December 31, 2023.
• Gross profit increased to $23.2 million for the nine months ended December 31, 2023.
• Sales orders increased to $55.7 million for the nine months ended December 31, 2023.
• Adjusted EBITDA improved to $0.5 million for the nine months ended December 31, 2023.

Negatives

• The company has an accumulated deficit of $(33.9) million as of December 31, 2023.
• The company is evaluating its ability to continue as a going concern.
• The company experienced a net loss of $4.2 million for the nine months ended December 31, 2023.
• The company has significant current liabilities of $54.9 million as of December 31, 2023.

Risks

• The company is evaluating its ability to continue as a going concern due to the recent business combination.
• The company has a significant accumulated deficit of $(33.9) million.
• The company is exposed to risks related to supply chain disruptions and inflation.
• The company is exposed to foreign currency fluctuations.
• The company is subject to the complexities and costs of EU MDR implementation.
• The company has a subjective acceleration clause in its credit facilities.
• The company has significant current liabilities of $54.9 million as of December 31, 2023.

Future Outlook

The company plans to continue to fund its growth through cash flows from operations and future debt and equity financing. Management expects that its cash and cash equivalents, together with cash provided by operating activities and proceeds from future debt and equity financings, will be sufficient to fund its operating expenses and capital expenditures requirements for at least the next 12 months.

Management Comments

• Management believes that Adjusted EBITDA provides investors with additional useful information in evaluating our performance.
• Management expects revenue to increase sequentially in future periods as it expects the demand for its products to expand in represented markets.
• Management expects cost of sales to increase in absolute dollars in future periods as it expects orders for its products to continue to grow and expects cost of sales per unit to decrease as leverage improves behind expected growth.
• Management expects selling, general and administrative expenses to increase for the foreseeable future as it scales headcount, expands hiring of engineers and designers, continues to invest in development of technology in order to drive the growth of the business, and as a result of operating as a public company.
• Management expects research and development costs to increase as it continues to invest in product design and technology to drive the growth of the business.

Industry Context

The announcement reflects a trend of consolidation in the medical technology sector, with companies seeking to expand their market reach and product offerings through mergers and acquisitions. The focus on robotic and VR technologies aligns with the industry's move towards innovative and digitally-enabled healthcare solutions.

Comparison to Industry Standards

• The revenue growth of 42.1% for the nine months ended December 31, 2023, is strong compared to the industry average, which is typically in the single-digit to low double-digit range for established medical device companies. Companies like Stryker and Medtronic, while much larger, often see growth in the mid-single digits.
• The reduction in net loss from $6.7 million to $4.2 million is a positive sign, but the company's continued losses and accumulated deficit are concerning compared to industry leaders who are typically profitable.
• The company's cash position of $2.8 million is relatively low compared to larger competitors, which typically have hundreds of millions or billions in cash reserves. For example, companies like Intuitive Surgical and Zimmer Biomet maintain significant cash balances.
• The company's adjusted EBITDA of $0.5 million is a significant improvement, but it is still low compared to industry benchmarks. Companies like ResMed and Align Technology typically have EBITDA margins in the 20-30% range.
• The company's reliance on debt financing and the subjective acceleration clauses in its credit facilities are risk factors that are not typical for larger, more established medical device companies.

Related Party Transactions

• Transactions with DIH China, a subsidiary of DIH Hong Kong, related to distribution services provided to the Company are disclosed as related party transactions.
• The company holds a promissory note receivable of $405 for payments made on behalf of DIH Cayman.
• The company entered into a cost sharing agreement with ATAC Sponsor LLC, agreeing to pay $610 in installments.
• The company entered into a cash settlement agreement with DIH Cayman and its subsidiaries, agreeing to pay a net settlement amount of approximately $182.

Stakeholder Impact

• Shareholders may be concerned about the company's accumulated deficit and going concern evaluation.
• Employees may be affected by the company's efforts to streamline its organization and cost structure.
• Customers may be impacted by potential supply chain disruptions and changes in product delivery timelines.
• Creditors may be concerned about the company's reliance on debt financing and the subjective acceleration clauses in its credit facilities.

Next Steps

• The company will continue to evaluate its ability to continue as a going concern.
• The company will focus on streamlining its organization and cost structure.
• The company will work to improve future revenue growth.
• The company will continue to fund its growth through cash flows from operations and future debt and equity financings.

Key Dates

Keywords

financial results, business combination, revenue, net loss, EBITDA, rehabilitation, medical devices, supply chain, merger, pro forma